NGD-4715
NGD-4715 is a drug developed by , which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal models it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed Phase I clinical trials in humans. Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets. All four laboratories were closed and sold, and no employees were retained. The structure of NGD-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.
Wikipage disambiguates
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
NGD-4715
NGD-4715 is a drug developed by , which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal models it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed Phase I clinical trials in humans. Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets. All four laboratories were closed and sold, and no employees were retained. The structure of NGD-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.
has abstract
NGD-4715 is a drug developed b ...... ,4-dimethoxybenzyl)piperazine.
@en
CAS number
873318-96-8
Wikipage page ID
23,508,254
page length (characters) of wiki page
Wikipage revision ID
1,013,618,495
Link from a Wikipage to another Wikipage
CAS number
INN
none
@en
SMILES
[H][C@@]12CCC[C@@H]C1=CC=CC=C1C
@en
wikiPageUsesTemplate
hypernym
comment
NGD-4715 is a drug developed b ...... ,4-dimethoxybenzyl)piperazine.
@en
label
NGD-4715
@en